Citius Pharmaceuticalsの空売り状況は、投資家がCitius Pharmaceuticalsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Citius Pharmaceuticals (NASDAQ:CTXR) 株価情報, 空売り情報

CITIUS PHARMACEUTICALS INC

Citius Pharma

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals Inc

It is that time again.
13Fs are beginning to flow into the SEC offices, and the mojo wires are burning up with media types and the Instant Experts of the Internet psychoanalyzing what Warren Buffett, Bill Ackman, and Cathie Wood have been buying and selling.
I do not care what they are doing.
There are millions of eyeballs following every move of the best-known investors, which will leave little opportunity for gaining useful insights or creating an edge.
For the next several days, all the crackerjack-box Nuclear Engineers and global trade experts of Twitter will be experts in the reasons and beliefs that drive Warren and Bill to buy what they bought and sell what they sold.
I would rather follow those investors that are out of the limelight putting up steady returns that crush the markets and avoid the spotlight.
Being one of a small handful of people stealing ideas from a brilliant investor can still create a meaningful edge.
Robotti and Company is a great example of an out-of-the-limelight investment firm that has been quietly beating the market for decades. It is worth the time to go through the quarterly filings and see what gems we can uncover.
The Thundering Herd of the Web will not be in front of you and bid the shares up several points before you can finish your search.
They are not a hot money shop that owns the market darlings of the day and hold stocks for a long time, so most of you reading this will also ignore them.
Very few people active in the markets today will care for Robotti&#8217;s five-year average holding period.
When it comes to finding true value in the markets, few have demonstrated the consistent discipline and unwavering commitment of Bob Robotti. What I&#8217;ve always admired about Robotti&#8217;s approach is that it isn&#8217;t flashy or complicated &#8211; it&#8217;s simply buying good businesses at bargain prices and having the patience to let the market eventually recognize their worth.
Robotti&#8217;s story is a perfect example of how focusing on fundamentals can build a successful investment career. After graduating from Bucknell University and earning his MBA in Accounting from Pace University, he started in public accounting. This might seem like an unlikely beginning for an investment legend, but those accounting skills would become the foundation of his analytical approach.
The turning point in Robotti&#8217;s career came during an audit assignment for Tweedy Browne, where conversations with Joe Reilly Sr. introduced him to value investing principles.
Think about that &#8211; while most young professionals were just trying to get their work done, Robotti was absorbing wisdom from a partner at one of the most respected value shops on Wall Street.
That&#8217;s how real investing education happens.
Before launching his own firm, Robotti cut his teeth as a vice president at Gabelli &amp; Company. Working alongside another value investing legend in Mario Gabelli surely sharpened his skills.
In 1983, Robotti partnered with Dan Eng to launch Robotti &amp; Eng, Inc. Their initial focus was uncovering undervalued opportunities in pink sheet equities.
This wasn&#8217;t glamorous work &#8211; they were digging through the market&#8217;s bargain bin while everyone else was chasing the hot stocks of the day.
The firm eventually evolved into Robotti &amp; Company, expanding their offerings while never abandoning their core value philosophy.
What&#8217;s remarkable about Robotti&#8217;s investment approach is its consistency. For over 40 years, he&#8217;s stuck to the classic Benjamin Graham principles that markets frequently misprice securities. While others chased quarterly estimates and momentum plays, Robotti focused on understanding businesses&#8217; normalized earnings power before the market caught on.
The lesson from Robotti&#8217;s career is straightforward: buy good businesses at bargain prices, focus on the long term, and ignore market noise. While everyone else is chasing the latest fad, deep value investors like Robotti quietly compound wealth year after year.
In a market dominated by AI, crypto, and whatever else CNBC is hyping this week, Robotti&#8217;s patient, disciplined approach is refreshing. Find businesses trading below intrinsic value, understand what the market is missing, and wait. That&#8217;s how real wealth is built in the stock market, and Bob Robotti has proven it for four decades.
Here are the top three largest purchases by Robotti and Company in the first quarter of 2025:
Tidewater Inc. (Ticker: TDW) is the global leader in offshore support vessels, serving the international energy industry with a fleet of workboats that transport crews, equipment, and supplies to offshore drilling platforms and production facilities. The company operates primarily in deepwater and harsh environment markets, with a presence in every major offshore basin, including the U.S. Gulf of Mexico, West Africa, the North Sea, and Southeast Asia.
Following a successful post-bankruptcy restructuring, Tidewater has refocused on disciplined capital allocation, maintaining one of the youngest and most capable fleets in the industry. With improving offshore exploration and production activity, tight vessel supply, and growing demand for high-spec tonnage, Tidewater is positioned to benefit from rising day rates and extended contract durations. The company has low leverage, strong free cash flow generation, and significant operating leverage as vessel utilization recovers, making it a compelling deep-value play for investors with a long-term horizon on offshore energy markets.
Robotti is obviously bullish on the offshore oil and gas business as he also was a buyer of SEACOR Marine Holdings (Ticker: SMHI).
SEACOR is one of those under-the-radar names that&#8217;s quietly critical to keeping the offshore energy world spinning. Based out of Houston, SEACOR runs a global fleet of support vessels—platform supply boats, fast crew movers, and liftboats that haul people, gear, and equipment out to oil rigs and wind installations all over the world. If something&#8217;s happening offshore, there&#8217;s a decent chance a SEACOR boat is nearby helping make it happen.
The business leans heavily into safety, reliability, and increasingly, greener operations. They&#8217;ve got a solid footprint in every major offshore basin, serving big-name oil companies, independents, and even the offshore wind crowd. It&#8217;s a gritty, asset-heavy business, but SEACOR&#8217;s diversified fleet and global reach give it staying power.
Legacy Housing Corporation (Ticker: LEGH) is one of those quietly solid businesses that doesn&#8217;t make a lot of headlines, but it keeps chugging along, making money and filling a real need. Headquartered in Bedford, Texas, Legacy is the fourth-largest manufacturer of mobile and tiny homes in the U.S., with a stronghold across the South.
They&#8217;ve been at it since 2005, and their model is pretty simple. They build affordable homes, sell them through a network of company stores and independent dealers, and offer financing so folks can actually afford them.
What sets Legacy apart is how integrated their business is. They manufacture the homes themselves, finance them, and even sell directly to communities and consumers. That vertical setup keeps margins healthy, and you can see it in the numbers.
While revenue dipped slightly in 2024 to $184 million, net income jumped over 13% to $61.6 million. That&#8217;s thanks to some smart moves on the finance side and keeping expenses under control.
In a world where affordable housing is in short supply and demand just keeps rising, Legacy Housing looks like a business that&#8217;s built to last and to keep throwing off cash along the way.
These three stocks will not be ranked at the top of today&#8217;s social media searches.
They will not get much, if any, airtime on CNBC or Fox Business.
They are, however, solid companies trading at bargain prices that could deliver huge gains over the next several years.

Opinion

LEGH

SMHI

Alpha Buying: Why Smart Money Is Moving Into Offshore and Affordable Housing

<a href="https://www.bloomberg.com/news/articles/2025-05-15/cvs-bids-for-rite-aid-stores-patient-files-in-pacific-northwest?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-15/cvs-bids-for-rite-aid-stores-patient-files-in-pacific-northwest?embedded-checkout=true</a>

News

General

'CVS Bids For Rite Aid Stores, Patient Files in Pacific Northwest'- Bloomberg

Oppenheimer analyst Colin Rusch maintains Aeva Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEVA#NASDAQ">AEVA</a>) with a Outperform and raises the price target from $9 to $18.

Price Target

Analyst Ratings

AEVA

Oppenheimer Maintains Outperform on Aeva Technologies, Raises Price Target to $18

Oppenheimer analyst Jay Olson maintains Jasper Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) with a Outperform and lowers the price target from $80 to $65.

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

Oppenheimer Maintains Outperform on Jasper Therapeutics, Lowers Price Target to $65

Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) is catching traders' attention again as its current price action closely resembles a major historical pattern that led to <a href="https://www.benzinga.com/money/dogecoin-doge-price-prediction">explosive gains in the past</a>.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.2282</td>
<td>-1.2%</td>
<td>+19.7%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001519</td>
<td>-2.9%</td>
<td>+9%</td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>$0.00001396</td>
<td>+1.8%</td>
<td>+36.6%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Trader Tardigrade dubbed this setup "Dogecoin Super Cycle 2," suggesting DOGE is at a key accumulation phase similar to the lead-up before its massive 2021 rally. 
Drawing parallels to the 2014–2018 macro pattern, Tardigrade believes the current structure implies substantial upside in the coming months.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> repeats the macro chart pattern in 2014-2018 &#x1f525;<a href="https://twitter.com/search?q=%24Doge&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$Doge</a> <a href="https://t.co/IoUwomhopW">pic.twitter.com/IoUwomhopW</a>
&mdash; Trader Tardigrade (@TATrader_Alan) <a href="https://twitter.com/TATrader_Alan/status/1923015587145580923?ref_src=twsrc%5Etfw">May 15, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
According to Bitcoinsensus, DOGE has already <a href="https://x.com/Bitcoinsensus/status/1923004315431518255">broken</a> out of a falling wedge, a bullish continuation pattern, and is now consolidating within a bull flag. The next technical target is $0.305, based on the measured move from the wedge breakout.
Similarly, Bluntz Capital <a href="https://x.com/Bluntz_Capital/status/1922845477512372626">remains</a> bullish, noting a classic inverse head and shoulders pattern with strong breakout volume. 
The ongoing pullback, he said, is healthy and could set the stage for further upside.
Statistics: Coinglass data shows Dogecoin liquidations in the past 24 hours stands at $13.4 million with long liquidations of $10.7 million. Open interest spiked to $3.03 billion.
Community News: In a recent post, 21Shares <a href="https://x.com/21Shares/status/1923021667254542341">highlighted</a> Dogecoin's cultural relevance, noting it "captures the spirit of the internet—from powering payments to supporting global causes."
The 21Shares Dogecoin ETP currently manages $2.15 million in assets, with a NAV of $7.66 as of May 14. The fund has returned 53.3% YTD, with a 2.2% daily gain.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45348013/dogecoin-jumps-4-can-doge-hit-1-soon">Dogecoin Jumps 4%: Can DOGE Hit $1 Soon?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$PEPE

$SHIB

Dogecoin Down 1% But This Pattern Signals A Breakout Is Imminent

Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent&#xAE; (alirocumab) from competing in the market
Jury awarded Regeneron $135.6 million dollars of compensatory damages and $271.2 million dollars in punitive damages
TARRYTOWN, N.Y., May 15, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) applauds the jury verdict in the U.S. District Court for the District of Delaware that found that Amgen Inc. violated antitrust and tort laws by creating a bundling scheme that illegally leveraged its blockbuster anti-inflammatory drugs Enbrel&#xAE; (etanercept) and Otezla&#xAE; (apremilast) to convince pharmacy benefit managers (PBMs) to select Repatha&#xAE; (evolocumab) as the exclusive PCSK9 category product over Praluent&#xAE; (alirocumab). The jury found that Amgen violated the Clayton Act, the Sherman Act, the New York State Donnelly Act, the California Cartwright Act and Delaware tort law.
Enbrel and Otezla are therapeutically different medicines that do not treat the heart conditions that Praluent or Repatha address. Amgen threatened to withhold rebates unless PBMs preferred Repatha and excluded Praluent. Amgen prevented Regeneron from competing on a level playing field and unfairly denied patients access to Praluent. This anticompetitive practice shut out an innovative therapy from the PCSK9 marketplace, not based on clinical merit or price. Because of Amgen's size and unrelated product portfolio, their anticompetitive actions ultimately hurt competition and patients.
The jury awarded Regeneron $135.6 million dollars of compensatory damages. The jury also awarded Regeneron $271.2 million dollars in punitive damages. Punitive damages may be awarded to punish a party for outrageous conduct and deter a party, and others like it, from engaging in similar conduct in the future.

REGN

Regeneron Pharma: Federal Court Jury Found Amgen Liable For Violating Antitrust And Tort Laws By Using Cross-Therapeutic Bundled Rebates To Prevent Praluent From Competing In Market; Jury Awarded Regeneron $135.6M Of Compensatory Damages And $271.2M In Punitive Damages

Needham analyst Mike Matson maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Buy and raises the price target from $100 to $108.

MMSI

Needham Maintains Buy on Merit Medical Systems, Raises Price Target to $108

Oppenheimer analyst Jeff Jones maintains Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) with a Outperform and lowers the price target from $26 to $25.

ALMS

Oppenheimer Maintains Outperform on Alumis, Lowers Price Target to $25

Oppenheimer analyst Tyler Batory maintains Toll Brothers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) with a Outperform and lowers the price target from $165 to $155.

Oppenheimer Maintains Outperform on Toll Brothers, Lowers Price Target to $155

WIIM

IXHL

IXHL stock has given up its prior gain. Incannex Healthcare shares were trading highera fter the company reported a year-over-year increase in Q3 EPS results.

B. Riley Securities analyst Yuan Zhi maintains Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) with a Buy and lowers the price target from $1.2 to $1.

HYPR

B. Riley Securities Maintains Buy on Hyperfine, Lowers Price Target to $1

CMS Energy Announces New Corporate Organizational Structure To Support Operational Transformation And Long-Term Company Strategy

NWTG

NWTG stock has given up its prior gain. Newton Golf Company shares were trading higher after the company reported a year-over-year increase in Q1 financial results.

B. Riley Securities analyst Lucas Pipes maintains Alpha Metallurgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMR#NYSE">AMR</a>) with a Buy and lowers the price target from $183 to $181.

B. Riley Securities Maintains Buy on Alpha Metallurgical, Lowers Price Target to $181

<a href="https://www.benzinga.com/personal-finance/25/05/45192749/ray-dalio-says-chasing-wealth-without-purpose-is-a-tragedy-dont-make-money-itself-the-goal">Ray Dalio</a>'s Bridgewater Associates just made a massive portfolio move that's bound to raise eyebrows <a href="https://www.benzinga.com/quote/SPY/news" target="_blank" rel="noreferrer noopener">on Wall Street</a>. 
<h2 class="wp-block-heading">Is Berkshire&#8217;s Portfolio Sending A Message</h2>
According to its first quarter <a href="https://www.sec.gov/Archives/edgar/data/1350694/000117266125001828/xslForm13F_X02/primary_doc.xml">13F filin</a>g, the world's largest hedge fund slashed its top holding — the SPDR S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) — by nearly 60%, dumping 4.9 million shares. The fund still holds over 3.3 million SPY shares, but the dramatic trim slashed its portfolio weighting from 22.1% to just 8.7%.
It didn't stop there. Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) all got haircuts, with share reductions of 18.7%, 31.5%, and 16% respectively. These aren't minor trims — they're deliberate signals. 
Dalio may no longer be Bridgewater's CEO, but his macro fingerprints still linger in the firm's playbook.
Read Also: <a href="https://www.benzinga.com/25/05/45442127/palantir-soars-500-in-a-year-while-unitedhealth-tanks-40-tech-leaves-healthcare-in-the-dust">Palantir Soars 500% In A Year While UnitedHealth Tanks 40% — Tech Leaves Healthcare In The Dust</a>
<h2 class="wp-block-heading">Gold In, Tech Out?</h2>
If there's a pivot in the air, it's sparkling — Bridgewater added a fresh position in SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), which now ranks in its top ten holdings. Combined with fresh buying in Alibaba Group Holding Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABAF#NYSE">BABAF</a>) and a double-down in emerging markets via the iShares Core MSCI Emerging Markets ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IEMG#NYSE">IEMG</a>), the shift feels tactical — away from frothy U.S. equities, toward value, hedges, and international exposure.
Interestingly, while SPY took a hit, its ETF cousins iShares Core S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVV#NYSE">IVV</a>) and IEMG saw inflows. It's not a total U.S. equity exodus — it's a reallocation. And that's a warning worth watching.
For holders of SPY, IVV, and VOO, the message is mixed. While SPY got snipped, IVV was topped up. Bridgewater's moves suggest caution, not panic — but if Dalio's reading tea leaves, he's seeing clouds.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45445101/rout-to-rally-sp-500-stages-fastest-flip-in-market-history-with-22-comeback">Rout To Rally: S&amp;P 500 Stages Fastest Flip In Market History With 22% Comeback</a></li>
</ul>
Image: Shutterstock

Hedge Funds

BABA

ALIBABA GROUP HOLDING LTD by Alibaba Group Holding Limited

BABAF

GOOG

GOOGL

IEMG

NVDA

Ray Dalio's Bridgewater Dumps SPY, Trims Nvidia, Meta, Alphabet — Bearish Vibes?

B. Riley Securities analyst Lucas Pipes maintains IREN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) with a Buy and raises the price target from $14 to $15.

IREN

B. Riley Securities Maintains Buy on IREN, Raises Price Target to $15

Boot Barn Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) posted downbeat earnings for its fourth quarter, but issued f<a href="https://www.benzinga.com/quote/BOOT/earnings">irst-quarter guidance with its midpoint above estimates.</a>
Boot Barn reported quarterly earnings of $1.22 per share, which missed the analyst consensus estimate of $1.24. Quarterly revenue of $453.75 million missed the Street estimate of $458.42 million.
"Our team delivered a solid finish to fiscal year 2025 highlighted by 15% annual total sales growth and 23% growth in earnings per diluted share, underscoring the ongoing resilience of our core consumer despite broader market uncertainties. The continued strength across major merchandise categories, channels, and geographies reaffirms the broad appeal of our brand and the effectiveness of our strategic initiatives," said CEO John Hazen.&nbsp;
Boot Barn said it expects first-quarter EPS of between $1.44 and $1.52, versus the $1.44 analyst estimate, and revenue in a range of $483 million to $491 million, versus the $486.49 million estimate.
The company also announced a $200 million share repurchase program.
Boot Barn shares gained 15% to trade at $152.74 on Thursday.
These analysts made changes to their price targets on Boot Barn following earnings announcement.
<ul class="wp-block-list">
<li>JP Morgan analyst Matthew Boss maintains Boot Barn with an Overweight rating and lowered the price target from $209 to $196.</li>
<li>UBS analyst Jay Sole maintained the stock with a Buy and raised the price target from $156 to $210.</li>
<li>Baird analyst Jonathan Komp maintained Boot Barn with an Outperform rating and raised the price target from $140 to $180.</li>
<li>B of A Securities analyst Jason Haas maintained the stock with a Buy and raised the price target from $160 to $173.</li>
<li>Piper Sandler analyst Peter Keith maintained Boot Barn with an Overweight rating and raised the price target from $162 to $184.</li>
</ul>
Considering buying BOOT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="587" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15140029/image-189-1024x587.png" alt="" class="wp-image-916990" style="width:612px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15140029/image-189-1024x587.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15140029/image-189-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15140029/image-189-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15140029/image-189.png 1095w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/25/05/45405004/jim-cramer-sofi-goes-to-new-highs-recommends-not-buying-this-health-care-stock">Jim Cramer: SoFi Goes To &#8216;New Highs,&#8217; Recommends Not Buying This Health Care Stock</a> </li>
</ul>
Photo via Shutterstock

Earnings

Markets

Trading Ideas

BOOT

These Analysts Revise Their Forecasts On Boot Barn After Q4 Results

Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $42.25, a high estimate of $56.00, and a low estimate of $36.00. This current average has increased by 6.96% from the previous average price target of $39.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1747332081_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Exelixis. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$56.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$38.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Jefferson Harralson</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$47.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$41.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Exelixis. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Exelixis compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Exelixis's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Exelixis's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EXEL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Exelixis analyst ratings.</a>
<h2>About Exelixis</h2>
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
<h3>Exelixis: A Financial Overview</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Exelixis's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 18.16%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 24.68%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 6.19%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Exelixis's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 4.73%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.09, Exelixis adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EXEL

Demystifying Exelixis: Insights From 8 Analyst Reviews

Financial giants have made a conspicuous bullish move on Robinhood Markets. Our analysis of options history for Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) revealed 40 unusual trades.
Delving into the details, we found 40% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $2,389,279, and 36 were calls, valued at $1,934,669.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $20.0 and $85.0 for Robinhood Markets, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Robinhood Markets stands at 5455.27, with a total volume reaching 34,663.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Robinhood Markets, situated within the strike price corridor from $20.0 to $85.0, throughout the last 30 days.
<h3>Robinhood Markets 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747332073_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HOOD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$9.0</td>
<td>$8.85</td>
<td>$8.99</td>
<td>$55.00</td>
<td>$2.0M</td>
<td>627</td>
<td>2.3K</td>
</tr>
<tr>
<td>HOOD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$15.55</td>
<td>$15.1</td>
<td>$15.1</td>
<td>$55.00</td>
<td>$362.4K</td>
<td>7.6K</td>
<td>1</td>
</tr>
<tr>
<td>HOOD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$2.73</td>
<td>$2.68</td>
<td>$2.73</td>
<td>$55.00</td>
<td>$246.2K</td>
<td>7.2K</td>
<td>1.9K</td>
</tr>
<tr>
<td>HOOD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/30/25</td>
<td>$1.44</td>
<td>$1.43</td>
<td>$1.44</td>
<td>$63.00</td>
<td>$191.9K</td>
<td>1.9K</td>
<td>1.5K</td>
</tr>
<tr>
<td>HOOD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.43</td>
<td>$1.4</td>
<td>$1.37</td>
<td>$70.00</td>
<td>$125.1K</td>
<td>9.7K</td>
<td>2.8K</td>
</tr>
</tbody>
</table>

<h3>About Robinhood Markets</h3>
Robinhood Markets Inc is creating a modern financial services platform. It designs its own products and services and delivers them through a single, app-based cloud platform supported by proprietary technology. Its vertically integrated platform has enabled the introduction of new products and services such as cryptocurrency trading, dividend reinvestment, fraud detection, derivatives, fractional shares, recurring investments, and others.
<h3>Present Market Standing of Robinhood Markets</h3>
<ul>
<li>Currently trading with a volume of 23,760,211, the HOOD's price is down by -2.48%, now at $59.87. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 83 days.</li>
</ul>
<h3>What Analysts Are Saying About Robinhood Markets</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $60.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Needham keeps a Buy rating on Robinhood Markets with a target price of $58. 
&#x2A; An analyst from JP Morgan has decided to maintain their Neutral rating on Robinhood Markets, which currently sits at a price target of $47. 
&#x2A; An analyst from Goldman Sachs persists with their Buy rating on Robinhood Markets, maintaining a target price of $64. 
&#x2A; Maintaining their stance, an analyst from Cantor Fitzgerald continues to hold a Overweight rating for Robinhood Markets, targeting a price of $60. 
&#x2A; Maintaining their stance, an analyst from Needham continues to hold a Buy rating for Robinhood Markets, targeting a price of $71. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Robinhood Markets with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

HOOD

This Is What Whales Are Betting On Robinhood Markets

Throughout the last three months, 25 analysts have evaluated Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">13</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Devon Energy, presenting an average target of $44.76, a high estimate of $56.00, and a low estimate of $35.00. Experiencing a 5.89% decline, the current average is now lower than the previous average price target of $47.56. 
<img src="https://www.benzinga.com/files/images/story/2025/1747332072_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Devon Energy is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neil Mehta</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$43.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$46.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$43.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Betty Jiang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$40.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Noah Hungness</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$42.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Betty Jiang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$38.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$56.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$41.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$54.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$40.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$44.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Paul Cheng</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$35.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$46.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$35.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$43.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Devin McDermott</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$47.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$46.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$42.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>John Freeman</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$46.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$52.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$44.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Subash Chandra</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$44.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Betty Jiang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$44.00</td>
<td>$43.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Devon Energy. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Devon Energy compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Devon Energy's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Devon Energy's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/DVN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Devon Energy analyst ratings.</a>
<h2>Delving into Devon Energy's Background</h2>
Devon Energy is an oil and gas producer with acreage in several top US shale plays. While roughly two thirds of its production comes from the Permian Basin, it also holds a meaningful presence in the Anadarko, Eagle Ford, and Bakken basins. At the end of 2024, Devon reported net proved reserves of 2.2 billion barrels of oil equivalent. Net production averaged roughly 848,000 barrels of oil equivalent per day in 2024 at a ratio of 73% oil and natural gas liquids and 27% natural gas.
<h3>Devon Energy: Financial Performance Dissected</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Over the 3M period, Devon Energy showcased positive performance, achieving a revenue growth rate of 23.8% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Energy sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Devon Energy's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 11.1%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Devon Energy's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.4% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.61%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.62.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Devon Energy Stock

Press Releases

Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Small Cap

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

Offerings

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Contracts

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock

Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

CTOR

CTXR

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Athira Pharma

Aytu BioPharma

Biofrontera

Cingulate

Cocrystal Pharma

Citius Pharmaceuticals

Evoke Pharma

Gelteq

Hoth Therapeutics

Impact BioMedical

Jaguar Health

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lipocine

Lyra Therapeutics

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

ProPhase Labs

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

SenesTech

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

Talphera

Traws Pharma

Titan Pharmaceuticals, Inc. - Common Stock

Titan Pharma

TherapeuticsMD

D. Boral Capital

HC Wainwright & Co.

EF Hutton

Screenshot 2024-08-06 at 7.17.40 PM

Biotech

TENK

Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology

Screenshot 2024-07-29 at 8.39.42 PM

From fighting cancer to treating bloodstream infections, Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is busy trying to solve some of the world&#39;s ills. That&#39;s picking up steam with two of its lead products close to commercialization. 

Comments

Citius Pharmaceuticals

空売り

Citius Pharmaceuticals (NASDAQ:CTXR) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル